By Katherine Hamilton
Shares of Prothena climbed Thursday after the company said a trial of its Parkinson's treatment suggests potential clinical benefits in the early stages of the disease, even though it missed its primary endpoint.
The stock was up 37.5% to $16.41 in recent trading and. It has fallen about 55% this year.
The study, conducted by Roche, investigated prasinezumab in almost 600 people with early-stage Parkinson's disease.
The treatment showed potential clinical effect, including a delay in motor progression, as well as consistent positive trends across multiple secondary and exploratory endpoints. There were no new safety issues.
The results will inform further clinical development of prasinezumab as a potential disease-modifying treatment for Parkinson's patients, the biotechnology company said.
Roche is evaluating the data and will work with health authorities to determine next steps, Prothena said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
December 19, 2024 15:21 ET (20:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。